Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
3.270
+0.280 (9.36%)
At close: Jun 26, 2026, 4:00 PM EDT
3.360
+0.090 (2.75%)
After-hours: Jun 26, 2026, 7:48 PM EDT
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,492,353
Market Cap
17.45M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Lunai Bioworks | 29 |
| Citius Pharmaceuticals | 23 |
| Atossa Therapeutics | 16 |
| Werewolf Therapeutics | 14 |
| Tempest Therapeutics | 5 |
| Exicure | 2 |
| GT Biopharma | 1 |
MBRX News
- 22 days ago - Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML - GlobeNewsWire
- 23 days ago - Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment - GlobeNewsWire
- 4 weeks ago - Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits - GlobeNewsWire
- 5 weeks ago - Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin - GlobeNewsWire
- 6 weeks ago - Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial - GlobeNewsWire
- 6 weeks ago - Moleculin Biotech Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Moleculin Biotech Earnings release: Q1 2026 - Filings
- 6 weeks ago - Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30 - TheFly